SCHEMBL18990983

SCHEMBL18990983

O=C(O)C(O)COc1ccc(-n2ccnc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.43
CYP2D6 P10635 4/20 0.43
CYP1A2 P05177 3/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 3/20 0.43
KMT2A Q03164 1/20 0.43
ADRB1 P08588 5/20 0.41
ADRB2 P07550 2/20 0.41
ADRB3 P13945 2/20 0.41
NAMPT P43490 1/20 0.40
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
PORCN Q9H237 1/20 0.38
CCNT1 O60563 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
HSF1 Q00613 1/20 0.37
TBXAS1 P24557 4/20 0.37
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18990982 1.00 CYP3A4 (0.43) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL31079944 0.84 ADRB1 (0.39) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL29357788 0.84 ADRB1 (0.39) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL18991608 0.79 CYP1A2 (0.37) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL18991611 0.79 CYP1A2 (0.37) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL20567583 0.78 NAMPT (0.38) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL20567585 0.78 NAMPT (0.38) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL18991950 0.76 CYP2D6 (0.48) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL31080645 0.76 CYP2D6 (0.48) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL20565988 0.76 CYP3A4 (0.41) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230543-B2 Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections MERCK SHARP & DOHME CORP. (US) 2022-01-25 US disclosed
EP-3390357-B1 BIARYL MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME (US) 2021-11-10 EP disclosed
US-20200361928-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORP. (US) 2020-11-19 US disclosed
US-20180339983-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORP. (US) 2018-11-29 US disclosed
EP-3390357-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS Merck Sharp & Dohme Corp. (US) 2018-10-24 EP disclosed
WO-2017106064-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORP. (US) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339983-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS BMX, BTK, ABCB11 CYP3A4 1016/4885CYP2D6 112/4885CYP1A2 253/4885
US-11230543-B2 Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections SQLE, ABCB11, BMX CYP3A4 946/4885CYP2D6 107/4885CYP1A2 119/4885
US-20200361928-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS ABCB11, SQLE, BMX CYP3A4 952/4885CYP2D6 96/4885CYP1A2 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.